论文部分内容阅读
目的观察支气管哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)应用噻托溴铵粉联合布地奈德福莫特罗吸入治疗的短期疗效。方法 78例支气管哮喘-慢性阻塞性肺疾病重叠综合征患者,随机分为实验组和对照组,每组39例。实验组采用噻托溴铵粉联合布地奈德福莫特罗吸入治疗,对照组采用布地奈德福莫特罗吸入治疗。观察临床治疗效果,对比治疗前后两组患者的肺功能。结果治疗4周后,实验组总控制有效率92.3%高于对照组74.4%,差异具有统计学意义(P<0.05)。治疗前两组患者第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、一氧化碳弥散量(DLCO)比较差异均无统计学意义(P>0.05);治疗后实验组患者FEV1、FVC、FEV1/FVC、DLCO均高于对照组,差异均具有统计学意义(P<0.05)。结论支气管哮喘-慢性阻塞性肺疾病重叠综合征患者应用噻托溴铵粉联合布地奈德福莫特罗吸入治疗时,短期疗效较好,可明显改善患者肺功能,促进患者生活质量的提升,可在临床进一步推广。
Objective To observe the short-term curative effect of bronchial asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) treated with tiotropium bromide combined with budesonide formoterol inhalation. Methods 78 cases of patients with bronchial asthma - chronic obstructive pulmonary disease overlap syndrome were randomly divided into experimental group and control group, 39 cases in each group. The experimental group received tiotropium bromide combined with budesonide formoterol inhalation, the control group with budesonide formoterol inhalation. Observe the clinical treatment effect, compare the two groups of patients before and after treatment of lung function. Results After 4 weeks of treatment, the total effective rate of experimental group was 92.3% higher than that of control group (74.4%), the difference was statistically significant (P <0.05). There was no significant difference in FEV1, FVC, FEV1 / FVC, DLCO between the two groups before treatment (P> 0.05). After treatment, the patients in experimental group FEV1, FVC, FEV1 / FVC, DLCO were higher than the control group, the difference was statistically significant (P <0.05). Conclusion In the patients with bronchial asthma and chronic obstructive pulmonary disease overlap syndrome, the short-term curative effect of tiotropium bromide combined with budesonide formoterol inhalation is better, which can obviously improve pulmonary function and promote the quality of life of patients, Can be further promoted in the clinic.